Itasetron

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581137

CAS#: 123258-84-4 (free base)

Description: Itasetron is a potent 5HT-3 receptor antagonist. Itasetron hydrochloride is a new 5-hydroxytryptamine3 (5-HT3) antagonist with potent antiemetic properties. It is more potent than ondansetron in animal models and in early clinical studies it demonstrates a long half-life and does not undergo hepatic biotransformation before elimination. itasetron hydrochloride is effective in the dose range 35-280 microg/kg in preventing cisplatin-induced emesis.


Chemical Structure

img
Itasetron
CAS# 123258-84-4 (free base)

Theoretical Analysis

MedKoo Cat#: 581137
Name: Itasetron
CAS#: 123258-84-4 (free base)
Chemical Formula: C16H20N4O2
Exact Mass: 300.1586
Molecular Weight: 300.36
Elemental Analysis: C, 63.98; H, 6.71; N, 18.65; O, 10.65

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 127618-28-4 (HCl)   123258-84-4 (free base)  

Synonym: Itasetron; DAU 6215CL; DAU6215CL; U 98079A; U-98079A; UNII-00S0D0OEKR;

IUPAC/Chemical Name: 1H-Benzimidazole-1-carboxamide, 2,3-dihydro-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-2-oxo, endo-

InChi Key: RWXRJSRJIITQAK-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H20N4O2/c1-19-11-6-7-12(19)9-10(8-11)17-15(21)20-14-5-3-2-4-13(14)18-16(20)22/h2-5,10-12H,6-9H2,1H3,(H,17,21)(H,18,22)

SMILES Code: O=C(N1C2=CC=CC=C2NC1=O)NC3CC(N4C)CCC4C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 300.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Patoia L, Del Favero A, Giglietti A, Malacarne P, Donati D, Indelli M, Bensi G, Palladino MA, Cigarini P, Kempe R, Voigt T. Intravenous itasetron: establishing the effective dose range for the prophylactic control of acute emesis in cancer patients undergoing high-dose cisplatin chemotherapy. Clin Oncol (R Coll Radiol). 1999;11(2):99-104. PubMed PMID: 10378635.

2: Goldschmidt H, Salwender H, Egerer G, Kempe R, Voigt T. Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy. Anticancer Drugs. 1997 Jun;8(5):436-44. PubMed PMID: 9215605.

3: Volonté M, Ceci A, Borsini F. Effect of the 5-hydroxytryptamine3 receptor antagonist itasetron (DAU 6215) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: an in vivo microdialysis study. J Pharmacol Exp Ther. 1995 Oct;275(1):358-67. PubMed PMID: 7562571.

4: Pitsikas N, Borsini F. Itasetron (DAU 6215) prevents age-related memory deficits in the rat in a multiple choice avoidance task. Eur J Pharmacol. 1996 Sep 12;311(2-3):115-9. PubMed PMID: 8891590.

5: Itasetron. DAU 6215, U 98079. Drugs R D. 1999 Oct;2(4):243-4. PubMed PMID: 10659399.

6: Pitsikas N, Brambilla A, Borsini F. DAU 6215, a novel 5-HT3 receptor antagonist, improves performance in the aged rat in the Morris water maze task. Neurobiol Aging. 1993 Nov-Dec;14(6):561-4. PubMed PMID: 8295658.

7: Schiavi GB, Brunet S, Rizzi CA, Ladinsky H. Identification of serotonin 5-HT4 recognition sites in the porcine caudate nucleus by radioligand binding. Neuropharmacology. 1994 Mar-Apr;33(3-4):543-9. PubMed PMID: 7984293.

8: Sagrada A, Turconi M, Bonali P, Schiantarelli P, Micheletti R, Montagna E, Nicola M, Algate DR, Rimoldi EM, Donetti A. Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation. Cancer Chemother Pharmacol. 1991;28(6):470-4. PubMed PMID: 1834359.

9: Invernizzi R, Pozzi L, Samanin R. Selective reduction of extracellular dopamine in the rat nucleus accumbens following chronic treatment with DAU 6215, a 5-HT3 receptor antagonist. Neuropharmacology. 1995 Feb;34(2):211-5. PubMed PMID: 7617146.

10: Rizzi CA, Prudentino A, Giraldo E. Effects on general behaviour and neurotransmitter functions of a new 5-hydroxytryptamine3 receptor antagonist with potential therapeutic relevance in central nervous system disturbances. Arzneimittelforschung. 1993 Oct;43(10):1033-41. PubMed PMID: 7903536.

11: Borsini F, Brambilla A, Cesana R, Donetti A. The effect of DAU 6215, a novel 5HT-3 antagonist, in animal models of anxiety. Pharmacol Res. 1993 Feb-Mar;27(2):151-64. PubMed PMID: 8097309.

12: Passani MB, Pugliese AM, Azzurrini M, Corradetti R. Effects of DAU 6215, a novel 5-hydroxytryptamine3 (5-HT3) antagonist on electrophysiological properties of the rat hippocampus. Br J Pharmacol. 1994 Jun;112(2):695-703. PubMed PMID: 8075890; PubMed Central PMCID: PMC1910391.

13: Brambilla A, Ghiorzi A, Pitsikas N, Borsini F. DAU 6215, a novel 5-HT3-receptor antagonist, selectively antagonizes scopolamine-induced deficit in a passive-avoidance task, but not scopolamine-induced hypermotility in rats. J Pharm Pharmacol. 1993 Sep;45(9):841-3. PubMed PMID: 7903377.

14: Malinowska B, Pawlak D, Buczko W. Influence of DAU 6215, a novel 5-HT3 receptor antagonist, on the cardiovascular system in anaesthetized and pithed rats. Agents Actions. 1992 Jul;36(3-4):230-6. PubMed PMID: 1529806.

15: Dumuis A, Sebben M, Monferini E, Nicola M, Turconi M, Ladinsky H, Bockaert J. Azabicycloalkyl benzimidazolone derivatives as a novel class of potent agonists at the 5-HT4 receptor positively coupled to adenylate cyclase in brain. Naunyn Schmiedebergs Arch Pharmacol. 1991 Mar;343(3):245-51. PubMed PMID: 1650917.

16: Baxter GS, Clarke DE. Benzimidazolone derivatives act as 5-HT4 receptor ligands in rat oesophagus. Eur J Pharmacol. 1992 Mar 3;212(2-3):225-9. PubMed PMID: 1601064.

17: Turconi M, Nicola M, Quintero MG, Maiocchi L, Micheletti R, Giraldo E, Donetti A. Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists. J Med Chem. 1990 Aug;33(8):2101-8. PubMed PMID: 1695682.

18: Pitsikas N, Brambilla A, Borsini F. Effect of DAU 6215, a novel 5-HT3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task. Pharmacol Biochem Behav. 1994 Jan;47(1):95-9. PubMed PMID: 8115433.

19: Prisco S, Pessia M, Ceci A, Borsini F, Esposito E. Chronic treatment with DAU 6215, a new 5-HT3 receptor antagonist, causes a selective decrease in the number of spontaneously active dopaminergic neurons in the rat ventral tegmental area. Eur J Pharmacol. 1992 Apr 7;214(1):13-9. PubMed PMID: 1582449.